![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SWISS MEDICA CONTINUES TO RECEIVE INTERNATIONAL ATTENTION FOR O24 FIBROMYALGIA
SWISS MEDICA CONTINUES TO RECEIVE INTERNATIONAL ATTENTION FOR O24 FIBROMYALGIA
June 8, 2006
Swiss Medica, Inc. announced today that international recognition continues to grow for its patented, all natural and clinically tested product O24 Fibromyalgia, with official approval by the Fibromyalgia Support Group Surrey & Sussex in the United Kingdom. O24 Fibromyalgia is the first clinically-tested product available in national pharmacies to help patients fight the intense, debilitating pain caused by Fibromyalgia.
CCN Matthews
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct